BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06 2019 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the compensation committee of BioCryst’s board of directors granted
two newly-hired employees options to purchase an aggregate
of 141,224 shares of BioCryst common stock on April 30, 2019
and May 1, 2019, respectively, as inducements material to each
employee entering into employment with BioCryst. The options were
granted in accordance with NASDAQ Listing Rule 5635(c)(4).
The options have an exercise price of $7.43
and $7.28 per share, which is equal to the closing price of
BioCryst common stock on each grant date. Each stock option vests
in four equal annual installments beginning on the one-year
anniversary of its grant date, in each case, subject to the new
employee’s continued service with the company. Each stock option
has a 10 year term and is subject to the terms and conditions of
BioCryst’s Inducement Equity Incentive Plan and a stock option
agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. BioCryst has several
ongoing development programs including BCX7353, an oral treatment
for hereditary angioedema, BCX9930, an oral Factor D inhibitor for
the treatment of complement-mediated diseases, galidesivir, a
potential treatment for Marburg virus disease and Yellow Fever, and
a preclinical program to develop oral ALK-2 inhibitors for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024